SBIR/STTR Research Award

STTR Phase I: Porous Walled Hollow Glass Microspheres (PWHGMs): A novel sustained drug delivery platform with unique flexible capabilities

Award identifier 8dbd4335d1be8af0feff5b20ef4c5694bcd37ed0037ecede44ad5b475c40aaa9Awarding agency National Science Foundation

Award amount

$255,391

Program and phase

STTR · Phase I

Award year

2021

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
National Science Foundation
Branch
Not reported
Recipient company
SPHEROFILL LLC
Proposal award date
2021-06-01
Contract end date
2022-05-31
UEI
TPD5PKHYK4C8
Solicitation number
Not reported
Topic code
PT

Research abstract

The broader impact / commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to develop completely new technology for extended-release drugs. More than half of people told to take medicine just twice daily have trouble remembering to take both doses on time, and some drugs require dosing three- or four- times daily. This NSF project aims to create a new drug delivery system capable of programmed release over days to even weeks. The first drug product will be a treatment for malaria, which affects over 300 million people each year. Children are the most vulnerable; every 30 seconds, a child dies from malaria. Current treatments require multiple pills taken four times a day for several days. The proposed research could be transformative by enabling a cost-effective treatment taken once a day or possibly just once. The project has an enormous potential impact as the technology could create an entirely new market for drugs and drug delivery strategies impossible with current knowledge. This Small Business Technology Transfer (STTR) Phase I project focuses on a novel drug delivery platform with unprecedented capabilities. Current technology has limited ability to package and control the release of challenging drugs that are: labile, peptide- or nucleic acid-based, very hydrophilic, or very hydrophobic. The microscopic ceramic microspheres invented in the USA for national defense form the core of the technology, which is now repurposed to advance the national health and welfare. They have a thin, porous shell and a large, hollow interior that can be loaded with solids, liquids, or even gasses. The microspheres can then be sealed, and the payload released over time. This project's overall goal is to develop the drug delivery platform by focusing on a predicate proof-of-concept: achieving extended, controlled release of the anti-malarial drug Artemether over one day or longer. Challenges include developing novel ways of reliably loading and sealing the microspheres with a waxy hydrophobic drug, new methods of analyzing the product, and optimizing the drug's programmed release over time. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

Technology keywords

Not reported

Agency intelligence

National Science Foundation

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.